The Senate Republicans’ bill to repeal and replace the Affordable Care Act would result in the loss of health insurance for 22 million Americans in 2026 relative to the number who would be insured under current law, according to the nonpartisan Congressional Budget Office’s report.
The Senate Republicans’ bill to repeal and replace the Affordable Care Act (ACA) would result in the loss of health insurance for 22 million Americans in 2026 relative to the number who would be insured under current law, according to the nonpartisan Congressional Budget Office’s (CBO) report. The CBO previously estimated that the House version of the bill, which passed in May, would result in 23 million Americans losing health insurance coverage. The report also found that, as soon as 2018, 15 million more people would be uninsured relative to current law. The legislation would decrease the federal deficit by $321 billion over 10 years.
Senate leaders today postponed a vote on the bill until after the July 4th congressional recess. With Democrats united against the legislation, there can be no more than 2 Republicans voting with Democrats against the motion to proceed. Currently, 4 Republicans have opposed the motion; 2 others have not yet declared opposition, but may also decide to oppose.
Among the key features of the Better Care Reconciliation Act of 2017 (BCRA) are the following:
The BCRA is opposed by many healthcare groups, including the American Medical Association and every major hospital association. Hospitals focused their concerns on proposed cuts to Medicaid, which provides health insurance to 73 million low-income and disabled Americans who would otherwise have no health insurance when they require hospitalization. The National Rural Health Association noted that small hospitals and rural hospitals are already struggling to “keep their lights on” and rely on Medicaid payments to survive.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.